AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03305653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal String Test (EST)
Description: The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
Study NCT04047394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant candida urate oxidase
Description: PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
Study NCT01218230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Pegaptanib
Description: Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
Study NCT00615758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib at the dose of 150 mg orally once a day continually until progression
Study NCT02273024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01594879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIrena(LNG-IUS), oral MPA
Description: 1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate
Study NCT01262053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Intervention
Description: When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
Study NCT04153032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: DTZ is a calcium channel blocker for the treatment of chronic anal fissure
Study NCT01262053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function.
Study NCT01262053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Parallel control with no intervention
Study NCT04153032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebo
Description: Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
Study NCT01408004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Tablet 800mg qd til progression
Study NCT01408004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: tablet 10 mg qd til progression
Study NCT01408004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Study NCT01408004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Study NCT03218904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose intake
Description: Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
Study NCT03218904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrates intake
Description: Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
Study NCT03992755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ861 Inhaled Treprostinil
Description: LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Study NCT02823028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.
Study NCT02823028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.
Study NCT04646707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae (ESP) Block with Lidocaine/Bupivacaine
Description: Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
Study NCT02823028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Guide
Description: A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules.
Study NCT04646707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae (ESP) Block with placebo
Description: Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
Study NCT02312960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data Collection
Description: No study treatment will be provided in this long term follow up study.
Study NCT03861975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer-Related Lymphedema Measurements
Description: All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
Study NCT01534819 — intervention group
Intervention type: DEVICE
Intervention: EndoAnchor™
Description: Use of the EndoAnchor™ in conjunction with endograft
Study NCT01534819 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular treament
Description: implantation of a device inserted through an artery
Study NCT02823028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tweet2Quit
Description: A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group.
Study NCT01294332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
Study NCT04629677 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT04629677 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04629677 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03196011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TKR with mechanical alignment method
Description: TKR implanted using traditional mechanical alignment methods
Study NCT03196011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TKR with alternative alignment method
Description: TKR implanted using alternative alignment methods
Study NCT04308174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Gem/Cis
Description: Neoadjuvant Durvalumab + Gemcitabine/Cisplatin
Study NCT04308174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gem/Cis
Description: Neoadjuvant Gemcitabine/Cisplatin
Study NCT04294628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04294628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04294628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04294628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04294628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04294628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04294628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study NCT06190340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: Administration orally.
Study NCT06190340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration orally.
Study NCT01408004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
Study NCT01408004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
Study NCT01259505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1
Description: CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT02324062 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
Study NCT02324062 — intervention group
Intervention type: OTHER
Intervention: Blood Draw and Baseline Questionnaire
Description: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
Study NCT04035005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
Study NCT04035005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The first dose of placebo will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single 600 mg infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending if the previous dose was administered in one or two infusion, should be maintained between each infusion.
Study NCT02823028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tweet2Quit
Description: A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group.
Study NCT03459846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV q4w
Study NCT03459846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
Study NCT03459846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for oral tablet BID
Study NCT01371994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral
Study NCT01371994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02095873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glyoxalase 1 (Glo1) inducer
Description: Dietary bioactive
Study NCT02095873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol, 108 mg
Study NCT00053677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
Study NCT00053677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For subjects who were randomly assigned to placebo.
Study NCT02143453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: 30 to 60-minute continuous exercise at 80% of the peak heart rate
Study NCT02143453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
Study NCT02825706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational physiotherapy group
Description: 20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
Study NCT02381717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultra-sound guide
Description: Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
Study NCT02381717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Study NCT02381717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Study NCT01439971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
Study NCT01439971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
Study NCT01439971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
Study NCT01439971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
Study NCT01439971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280602
Description: 30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
Study NCT03325348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Description: Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
Study NCT03325348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
Study NCT00578877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SILCS Diaphragm
Description: SILCS Diaphragm used with 5 ml gel
Study NCT00578877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SILCS Diaphragm
Description: SILCS Diaphragm used with 5 ml gel
Study NCT00578877 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nonoxynol-9 Gel
Description: Gynol II (2% N-9 gel)
Study NCT00578877 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Buffer Gel
Description: Buffer Gel
Study NCT01468233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT01468233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection
Study NCT01468233 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection
Study NCT02323685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
Study NCT03706742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed outreach
Description: The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
Study NCT03363087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping and ablation
Description: Ultra high density scar mapping Collection of impedance data during ablation
Study NCT05748028 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
Study NCT05748028 — intervention group
Intervention type: OTHER
Intervention: Administration of Clinical scales
Description: All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
Study NCT04975139 — intervention group
Intervention type: DEVICE
Intervention: RS-fMRI
Description: Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
Study NCT03366272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
Study NCT03366272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: eight cycles of R-GemOx in 2-wk intervals
Study NCT03366272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: eight cycles of R-GemOx in 2-wk intervals
Study NCT03366272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: eight cycles of (R)-GemOx in 2-wk intervals
Study NCT03366272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: eight cycles of (R)-GemOx in 2-wk intervals